Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Verification report on the deposit and use of raised funds
Dahuhezi [2022] No. 007794
Da Hua Certified Public Accountants (special general partnership)
Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Verification report on the deposit and use of raised funds
(2021)
Table of contents page 1. Verification report on the deposit and use of raised funds 1-2. Special report on the deposit and use of raised funds 1-4 in Fujian Cosunter Pharmaceutical Co.Ltd(300436) 2021
Dahua Certified Public Accountants (special general partnership) 12 / F, building 7, No. 16 courtyard, Middle West Fourth Ring Road, Haidian District, Beijing [100039] Tel: 86 (10) 58350011 Fax: 86 (10) 58350006 www.dahua-cpa com. Verification report on the deposit and use of raised funds
Dahuhezi [2022] No. 007794 Fujian Cosunter Pharmaceutical Co.Ltd(300436) :
We have reviewed the attached Fujian Cosunter Pharmaceutical Co.Ltd(300436) (hereinafter referred to as Fujian Cosunter Pharmaceutical Co.Ltd(300436) ) special report on the deposit and use of raised funds in 2021 (hereinafter referred to as “special report on raised funds”).
1、 Responsibilities of the board of directors
Fujian Cosunter Pharmaceutical Co.Ltd(300436) the responsibility of the board of directors is to prepare the special report on raised funds in accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) of China Securities Regulatory Commission, the guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM issued by Shenzhen Stock Exchange and relevant format guidelines, And ensure that its contents are true, accurate and complete, and there are no false records, misleading statements or major omissions.
2、 Responsibilities of Certified Public Accountants
Our responsibility is to give assurance opinions on the special report of Fujian Cosunter Pharmaceutical Co.Ltd(300436) raised funds based on the implementation of assurance work. We have carried out the assurance business in accordance with the provisions of other assurance business standards for Chinese certified public accountants No. 3101 – assurance business other than audit or review of historical financial information. The standard requires us to plan and implement assurance work to obtain reasonable assurance on whether there is no material misstatement in the special report of Fujian Cosunter Pharmaceutical Co.Ltd(300436) raised funds.
In the assurance process, we have implemented procedures including understanding, inquiry, inspection, recalculation and other procedures that we deem necessary. We believe that our assurance work provides a reasonable basis for expressing opinions.
3、 Assurance conclusion
We believe that the special report on Fujian Cosunter Pharmaceutical Co.Ltd(300436) raised funds is prepared in accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies (revised in 2022) issued by China Securities Regulatory Commission, the guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM issued by Shenzhen Stock Exchange and relevant format guidelines in all major aspects, It fairly reflects the deposit and use of raised funds in Fujian Cosunter Pharmaceutical Co.Ltd(300436) 2021 in all major aspects.
4、 Restrictions on the users and purposes of the report
This report is only for the purpose of disclosure of Fujian Cosunter Pharmaceutical Co.Ltd(300436) annual report and shall not be used for any other purpose. We agree to take this report as a necessary document of Fujian Cosunter Pharmaceutical Co.Ltd(300436) annual report, submit it together with other documents and disclose it to the public. Dahua Certified Public Accountants (special general partnership) Chinese certified public accountant:
(project partner) Wang Qinglian
Beijing, China
Chinese certified public accountant:
Lai Zhenye
April 21, 2002
Fujian Cosunter Pharmaceutical Co.Ltd(300436) 2021 special report on the deposit and use of raised funds
Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Special report on the deposit and use of raised funds in 2021
1、 Basic information of raised funds
With the approval of China Securities Regulatory Commission zjxk [2020] No. 2748 and the consent of Shenzhen Stock Exchange, the company issued 18777000 ordinary shares (A shares) to specific objects by the lead underwriter Citic Securities Company Limited(600030) in June 2021, with a par value of 1 yuan per share and an issue price of 27.40 yuan per share. As of June 21, 2021, the company has raised a total of 51448980000 yuan, deducting 1490566038 yuan of issuance expenses (excluding tax), and the net amount of raised funds is 49958413962 yuan.
As of June 21, 2021, all the above raised funds have been in place and have been verified and confirmed by Dahua Certified Public Accountants (special general partnership) with the capital verification report “Dahua Yan Zi [2021] No. 000437”.
As of December 31, 2021, the company has invested 25676241037 yuan in the raised fund projects, of which: the company invested 5316673748 yuan in the raised fund projects with its own funds in advance before the raised funds are in place; The raised capital used in this year is 20359567289 yuan. The net amount of accumulated interest income of raised funds after deducting bank handling charges is 163372766; As of December 31, 2021, the balance of the special account for raised funds was 24445545691 yuan.
2、 Management of raised funds
In order to standardize the management and use of raised funds and protect the rights and interests of investors, the company has formulated the measures for the administration of Fujian Cosunter Pharmaceutical Co.Ltd(300436) raised funds (hereinafter referred to as the “measures”) in accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of Shenzhen Stock Exchange gem and other laws and regulations and in combination with the actual situation of the company, The management measures was revised and adopted at the 2017 annual general meeting of shareholders on April 13, 2018.
According to the requirements of the management measures and in combination with the business needs of the company, the company opened a special account for raised funds in Industrial Bank Co.Ltd(601166) and signed the tripartite supervision agreement for raised funds with Citic Securities Company Limited(600030) , Industrial Bank Co.Ltd(601166) Fuzhou Huanqiu sub branch on July 5, 2021; In order to ensure the smooth implementation of the project in which the company issues shares to specific objects, based on the implementation subject of the project and the actual needs of project construction, the company uses part of the raised funds to increase the capital of its wholly-owned subsidiary Fujian Fujian Cosunter Pharmaceutical Co.Ltd(300436) Jintang Pharmaceutical Co., Ltd. (hereinafter referred to as “Jintang pharmaceutical”) and its holding subsidiary Jiangsu Zhongxing Pharmaceutical Co., Ltd. (hereinafter referred to as “ZTE pharmaceutical”). Jintang pharmaceutical opened a special account for raising funds in China Merchants Bank Co.Ltd(600036) and signed page 1 of the special report on raising funds with Fujian Cosunter Pharmaceutical Co.Ltd(300436) , Citic Securities Company Limited(600030) , China Merchants Bank Co.Ltd(600036) Fuzhou branch on July 20, 2021
Fujian Cosunter Pharmaceutical Co.Ltd(300436) 2021 special report on the deposit and use of raised funds
Four party fund supervision agreement; ZTE pharmaceutical opened a special account for raised funds in China Minsheng Banking Corp.Ltd(600016) china, and signed the four party supervision agreement for raised funds with Fujian Cosunter Pharmaceutical Co.Ltd(300436) Citic Securities Company Limited(600030) China Minsheng Banking Corp.Ltd(600016) fuzhou branch on July 20, 2021; Strict examination and approval procedures shall be implemented for the use of raised funds to ensure that the special funds are used for special purposes; The authorized recommendation representative may inquire the information of the special account for raised funds at the bank that has opened the special account for raised funds at any time, and require the recommendation representative to conduct on-site investigation on the management and use of raised funds at least once a quarter.
According to the recommendation agreement signed between the company and Citic Securities Company Limited(600030) and the above-mentioned agreement, if the amount withdrawn by the company (including Jintang pharmaceutical and ZTE pharmaceutical) from the deposit account of raised funds reaches RMB 10 million or 10% of the net raised funds (whichever is lower), the company shall notify Citic Securities Company Limited(600030) . There is no significant difference between the regulatory agreement and the model regulatory agreement of Shenzhen Stock Exchange, and the regulatory agreement has been effectively implemented.
As of December 31, 2021, the storage of raised funds is listed as follows:
Monetary unit: RMB
Bank name account number initial deposit amount due date balance storage method Industrial Bank Co.Ltd(601166) Fuzhou Huanqiu sub branch 1181101 Anhui Deli Household Glass Co.Ltd(002571) 425038898 Shenzhen Kaifa Technology Co.Ltd(000021) 634100304 current China Merchants Bank Co.Ltd(600036) Fuzhou branch 5919074296103011192395534 current China Minsheng Banking Corp.Ltd(600016) Fuzhou branch 6325338931619049853 total current 503889800 Hangzhou Great Star Industrial Co.Ltd(002444) 5545691
Note: the difference between the balance of raised funds of 2428217 million yuan and the balance of special account of raised funds of 2444554 million yuan in the statement of use of raised funds is the accumulated amount of interest, account maintenance fee, issuance fee, input tax, etc. 3、 Use of raised funds in 2021
See the attached table “use of raised funds” for details.
4、 Change the use of funds for investment projects with raised funds
The company does not change the raised investment projects.
5、 Problems in the use and disclosure of raised funds
The information about the use of raised funds disclosed by the company is timely, true, accurate and complete, and there are no violations in the use and management of raised funds.
Fujian Cosunter Pharmaceutical Co.Ltd(300436) (seal) page 2 of special report 1 on April 21, 2002
Fujian Cosunter Pharmaceutical Co.Ltd(300436) 2021 special report on the deposit and use of raised funds
Use of raised funds
Prepared by: Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Monetary unit: RMB 10000
Total amount of raised funds 4995841 total amount of raised funds invested in this year
